On July 25, 2024 Hoffmann-La Roche reported its sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised (Presentation, Hoffmann-La Roche, JUL 25, 2024, View Source [SID1234646007]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!